References
1. Lalla, J., et al.: J. Pharm. Biomed. Anal., 11, 385 (1993). 2. Bolaji, O.O., et al.: Eur. J. Drug Metab. Pharmacokinet., 21, 217 (1996). 3. Kraemer, T., et al.: Drug Metab. Dispos., 28, 339. 4. Kapui, Z., Bence, J., Boronkay, E., et al. Behavioural effects of selective PDE4 inhibitors in relation to inhibition of catalytic activity and competition for [3H]rolipram binding. Neurobiology (Bp) 7(1), 71-73 (1999). 5. Tömösközi, Z., Finance, O., and Arányi, P. Drotaverine interacts with the L-type Ca2+ channel in pregnant rat uterine membranes. Eur. J. Pharmacol. 449(1-2), 55-60 (2002). 6. Madhu, C., Mahavarkar, S., and Bhave, S. A randomised controlled study comparing Drotaverine hydrochloride and Valethamate bromide in the augmentation of labour. Arch. Gynecol. Obstet. 282(1), 11-15 (2010).USBio References
No references available
TDS
NCBI
UniProt
Tech Support
Customer Service
